Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Dermatology

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 48 articles:
HTML format
Text format



Single Articles


    August 2017
  1. WISTUBA-HAMPRECHT K, Pawelec G
    KEYNOTE-006: a success in melanoma, but a long way to go.
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31816.
    PubMed     Text format    


  2. SCHACHTER J, Ribas A, Long GV, Arance A, et al
    Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Lancet. 2017 Aug 16. pii: S0140-6736(17)31601.
    PubMed     Text format     Abstract available


    June 2017
  3. NASH P, Kirkham B, Okada M, Rahman P, et al
    Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
    Lancet. 2017;389:2317-2327.
    PubMed     Text format     Abstract available


  4. PRINCE HM, Kim YH, Horwitz SM, Dummer R, et al
    Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Lancet. 2017 Jun 6. pii: S0140-6736(17)31266.
    PubMed     Text format     Abstract available


  5. PORCU P, Sahu J
    A positive randomised trial in cutaneous T-cell lymphoma.
    Lancet. 2017 Jun 6. pii: S0140-6736(17)31473.
    PubMed     Text format    


  6. REICH K, Papp KA, Blauvelt A, Tyring SK, et al
    Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Lancet. 2017 Jun 5. pii: S0140-6736(17)31279.
    PubMed     Text format     Abstract available


  7. BACHELEZ H
    Interleukin 23 inhibitors for psoriasis: not just another number.
    Lancet. 2017 Jun 5. pii: S0140-6736(17)31474.
    PubMed     Text format    


    May 2017
  8. MAR VJ, Scolyer RA, Long GV
    Computer-assisted diagnosis for skin cancer: have we been outsmarted?
    Lancet. 2017;389:1962-1964.
    PubMed     Text format    


  9. PAPP K, Thaci D, Marcoux D, Weibel L, et al
    Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Lancet. 2017 May 4. pii: S0140-6736(17)31189.
    PubMed     Text format     Abstract available


  10. STROWD LC, Feldman SR
    Dupilumab for atopic dermatitis.
    Lancet. 2017 May 4. pii: S0140-6736(17)31192.
    PubMed     Text format    


  11. BLAUVELT A, de Bruin-Weller M, Gooderham M, Cather JC, et al
    Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Lancet. 2017 May 4. pii: S0140-6736(17)31191.
    PubMed     Text format     Abstract available


  12. KIVELEVITCH D, Menter A
    Adalimumab in paediatric psoriasis.
    Lancet. 2017 May 4. pii: S0140-6736(17)31190.
    PubMed     Text format    


  13. DUONG TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O, et al
    Severe cutaneous adverse reactions to drugs.
    Lancet. 2017 May 2. pii: S0140-6736(16)30378.
    PubMed     Text format     Abstract available


    April 2017
  14. BOLINDER J, Antuna R, Geelhoed-Duijvestijn P, Kroger J, et al
    Cutaneous adverse events related to FreeStyle Libre device - Authors' reply.
    Lancet. 2017;389:1396-1397.
    PubMed     Text format    


  15. BRAHIMI N, Potier L, Mohammedi K
    Cutaneous adverse events related to FreeStyle Libre device.
    Lancet. 2017;389:1396.
    PubMed     Text format    


    January 2017
  16. VICTORA CG, Castro MC, Franca GV, Schuler-Faccini L, et al
    Zika rash and increased risk of congenital brain abnormalities - Authors' reply.
    Lancet. 2017;389:152.
    PubMed     Text format    


  17. GERARDIN P, Cao-Lormeau VM, Musso D, Despres P, et al
    Zika rash and increased risk of congenital brain abnormalities.
    Lancet. 2017;389:151-152.
    PubMed     Text format    


  18. LEAUTE-LABREZE C, Harper JI, Hoeger PH
    Infantile haemangioma.
    Lancet. 2017 Jan 12. pii: S0140-6736(16)00645.
    PubMed     Text format     Abstract available


  19. THE LANCET
    Trastuzumab emtansine and cost-based decision making.
    Lancet. 2017;389:2.
    PubMed     Text format    


    December 2016
  20. WARREN RB, Mrowietz U, von Kiedrowski R, Niesmann J, et al
    An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2016 Dec 21. pii: S0140-6736(16)32127.
    PubMed     Text format     Abstract available


  21. GLADMAN DD
    Should methotrexate remain the first-line drug for psoriasis?
    Lancet. 2016 Dec 21. pii: S0140-6736(16)32574.
    PubMed     Text format    


    November 2016
  22. CRISTOFANILLI M
    Metastatic breast cancer: focus on endocrine sensitivity.
    Lancet. 2016 Nov 28. pii: S0140-6736(16)32418.
    PubMed     Text format    


  23. ROBERTSON JF, Bondarenko IM, Trishkina E, Dvorkin M, et al
    Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.
    Lancet. 2016 Nov 28. pii: S0140-6736(16)32389.
    PubMed     Text format     Abstract available


    October 2016
  24. ZINK A, Bohner A, Schuch A, Biedermann T, et al
    Systemic mastocytosis with generalised skin involvement.
    Lancet. 2016 Oct 13. pii: S0140-6736(16)31710.
    PubMed     Text format    


  25. FINNERTY CC, Jeschke MG, Branski LK, Barret JP, et al
    Hypertrophic scarring: the greatest unmet challenge after burn injury.
    Lancet. 2016;388:1427-1436.
    PubMed     Text format     Abstract available


    September 2016
  26. THE LANCET
    Balancing the benefits and risks of choice.
    Lancet. 2016;388:1129.
    PubMed     Text format    


    August 2016
  27. DE LAVAL F, Matheus S, Maquart M, Yvrard E, et al
    Prospective Zika virus disease cohort: systematic screening.
    Lancet. 2016;388:868.
    PubMed     Text format    


    July 2016
  28. NATHWANI AC, Down JF, Goldstone J, Yassin J, et al
    Polonium-210 poisoning: a first-hand account.
    Lancet. 2016 Jul 22. pii: S0140-6736(16)00144.
    PubMed     Text format     Abstract available


  29. MATONO T, Kato Y, Yotsu R, Ohmagari N, et al
    Duplicate publication.
    Lancet. 2016;388:238.
    PubMed     Text format    


  30. STAHEL PF
    The inherent dangers of high-dose steroids for acute inflammatory conditions.
    Lancet. 2016;388:102.
    PubMed     Text format    


  31. LYNCH RW, Soane T, Gibson R, Pal S, et al
    Bilateral lower limb weakness in acute severe ulcerative colitis.
    Lancet. 2016;388:101-2.
    PubMed     Text format    


    June 2016
  32. FRANCA GV, Schuler-Faccini L, Oliveira WK, Henriques CM, et al
    Congenital Zika virus syndrome in Brazil: a case series of the first 1501 livebirths with complete investigation.
    Lancet. 2016 Jun 29. pii: S0140-6736(16)30902.
    PubMed     Text format     Abstract available


  33. RUPERTO N, Pistorio A, Ravelli A, Angioloni S, et al
    The PRINTO juvenile dermatomyositis trial - Authors' reply.
    Lancet. 2016;387:2601.
    PubMed     Text format    


  34. DALE A, Milosevic I, Goldacre B
    The PRINTO juvenile dermatomyositis trial.
    Lancet. 2016;387:2600-1.
    PubMed     Text format    


  35. KHANNA D, Denton CP, Jahreis A, van Laar JM, et al
    Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
    Lancet. 2016;387:2630-40.
    PubMed     Text format     Abstract available


  36. DISTLER O, Distler JH
    Tocilizumab for systemic sclerosis: implications for future trials.
    Lancet. 2016;387:2580-1.
    PubMed     Text format    


  37. OHUCHI N, Suzuki A, Yamamoto S, Kuriyama S, et al
    Adjunctive ultrasonography for breast cancer screening - Authors' reply.
    Lancet. 2016;387:2381-2.
    PubMed     Text format    


  38. AUTIER P, Boniol M
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2380.
    PubMed     Text format    


  39. FUJITA T
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2380-1.
    PubMed     Text format    


  40. DALE A, Slade E, Heneghan C
    Adjunctive ultrasonography for breast cancer screening.
    Lancet. 2016;387:2379-80.
    PubMed     Text format    


    May 2016
  41. RUSSELL P, Floridis J
    Hypertrichosis lanuginosa acquisita: a rare dermatological disorder.
    Lancet. 2016;387:2035.
    PubMed     Text format    


  42. BERNSTEIN M
    Intraoperative radiation therapy for breast cancer: a patient's view.
    Lancet. 2016;387:1904-5.
    PubMed     Text format    


  43. GUILLEVIN L, Regent A
    Treating giant-cell arteritis: is IL-6 the cytokine to target?
    Lancet. 2016;387:1882-1883.
    PubMed     Text format    


    April 2016
  44. STRNAD V, Uter W, Polgar C
    Partial breast irradiation and the GEC-ESTRO trial - Authors' reply.
    Lancet. 2016;387:1718-9.
    PubMed     Text format    


  45. VICINI F, Shah C, Arthur D, Khan A, et al
    Partial breast irradiation and the GEC-ESTRO trial.
    Lancet. 2016;387:1717-8.
    PubMed     Text format    


  46. VAIDYA JS, Bulsara M, Wenz F, Tobias JS, et al
    Partial breast irradiation and the GEC-ESTRO trial.
    Lancet. 2016;387:1717.
    PubMed     Text format    


  47. KIRBY T
    Profile: Liverpool School of Tropical Medicine, UK.
    Lancet. 2016;387:1502.
    PubMed     Text format    


    March 2016
  48. VILLIGER PM, Adler S, Kuchen S, Wermelinger F, et al
    Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Lancet. 2016 Mar 4. pii: S0140-6736(16)00560.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: